ACM
EGRX

AlphaCrest Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

AlphaCrest Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,085
Closed -$330K – 1336
2020
Q4 		$330K Sell
7,085
-4,730
-40% -$221K 0.03% 876
2020
Q3 		$502K Buy
+11,815
New +$517K 0.05% 582

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AlphaCrest Capital Management's EGRX Position: Q1 2021 in Review

AlphaCrest Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2021, closing a stake of 7,085 shares — an estimated $330K sold.

AlphaCrest Capital Management first reported a position in EGRX in Q3 2020 and held it in 2 quarters. The position peaked at $502K in Q3 2020. 155 funds tracked by Wall St. Rank hold EGRX as of Q1 2021.

  • AlphaCrest Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 7,085 Eagle Pharmaceuticals, Inc. shares in Q1 2021, an estimated $330K.
  • AlphaCrest Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2020 and held it in 2 quarters.
  • AlphaCrest Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $502K in Q3 2020.
  • 155 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2021.

Based on AlphaCrest Capital Management's 13F filing for Q1 2021, filed 13 May 2021.